Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis

Immunol Allergy Clin North Am. 2017 May;37(2):369-396. doi: 10.1016/j.iac.2017.01.010.


Immunoglobulin (Ig) E-mediated food allergy and eosinophilic esophagitis (EoE) are chronic, allergen-mediated disorders characterized by an aberrant TH2 immune response. The development and investigation of biologics for the treatment of IgE-mediated food allergy and eosinophilic esophagitis have provided further insight into the pathophysiology and management of these disorders. This article provides an overview of biologic therapies that are being investigated or have potential as treatments for IgE-mediated food allergy and eosinophilic esophagitis. Identification of EoE phenotypes that are responsive to biologics and investigation of biologics combined with other therapies may help elucidate a role for biologics in EoE.

Keywords: Anti-IgE; Anti–IL-13; Anti–IL-5; Eosinophilic esophagitis; Food allergy; OC000459; QAX576.

Publication types

  • Review

MeSH terms

  • Allergens / immunology
  • Antibodies, Anti-Idiotypic / pharmacology
  • Antibodies, Anti-Idiotypic / therapeutic use
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • Biological Therapy* / methods
  • Biomarkers
  • Clinical Trials as Topic
  • Eosinophilic Esophagitis / immunology*
  • Eosinophilic Esophagitis / therapy*
  • Food Hypersensitivity / immunology*
  • Food Hypersensitivity / therapy*
  • Humans
  • Immunoglobulin E / immunology*
  • Molecular Targeted Therapy
  • Receptors, Interleukin-13 / antagonists & inhibitors
  • Receptors, Interleukin-5 / antagonists & inhibitors
  • Treatment Outcome


  • Allergens
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Biological Products
  • Biomarkers
  • Receptors, Interleukin-13
  • Receptors, Interleukin-5
  • anti-IgE antibodies
  • Immunoglobulin E